Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
about
Creating an effective clinical registry for rare diseasesRisk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialistsObeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selectionRecent advances in the diagnosis and treatment of primary biliary cholangitis.Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic AcidPredicting Outcomes of Primary Biliary Cholangitis Using the GLOBE Score.Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary CholangitisA contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology.Emerging drugs for the treatment of Primary Biliary Cholangitis.Management of cholestatic disease in 2017.Finding the cure for primary biliary cholangitis - Still waiting.Geoepidemiology and changing mortality in primary biliary cholangitis.Old and new treatments for primary biliary cholangitis.Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis.Novel strategies and therapeutic options for the management of primary biliary cholangitis.Treatment of PBC-A step forward.A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.Editorial: scoring systems in primary biliary cholangitis - time to make a move. Authors' reply.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis.Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea.Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.A brief review on prognostic models of primary biliary cholangitis.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Investigational drugs in phase II clinical trials for primary biliary cholangitis.Primary biliary cholangitis: new treatments for an old disease.NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population.Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.Biomarkers for primary biliary cholangitis: current perspectives.External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid.A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis.Increased expression and altered localization of cathepsin Z are associated with progression to jaundice stage in primary biliary cholangitis
P2860
Q26741126-1D745C54-301A-4B7F-B656-954191056884Q26796355-CFBBCA24-B99C-4E4E-8CDA-47D79E8C8E06Q28072209-6855F617-389F-4D31-8BBF-A07FB4E8B4EAQ28076353-1DFCB4CA-E39D-40A9-B127-ABF70DDDC86EQ33840969-75D52887-B4FD-40E8-AE1A-C91F36679634Q33920325-DF85B3D0-207C-481D-8F48-88C49B4CEB96Q36848456-0EEBCF78-9EB8-4767-A3B2-6C754C208A05Q36914749-FC5CBE85-F8ED-4923-8358-ED7D5E5DFC6DQ37135580-FD5B4A9D-B6E0-4AD6-91FA-5135A55B62CBQ38620686-45E15049-E9DF-462E-B2B4-8B03B68D8DD8Q38744215-8888634E-7648-457C-B2EA-D8B82CBED7C0Q38774857-CB734010-FE81-413F-A47C-6696F9B711D9Q38858980-7FD9E5F4-B358-4384-9160-C66F4132EE1AQ39213467-467522F2-5BCB-410A-A604-9557F3DF44BBQ39216355-6FF8F03D-BDBC-4903-B656-6EE21139E522Q39542696-89119071-EC56-41CE-9B24-587554E6E1CCQ39584105-3AEACDCB-0B6A-492B-BA01-3307D579AF93Q41531249-0DFCEFD6-0971-4BE0-B203-9DDE1167C2B6Q42330772-9DC3801F-D112-4621-A5FA-7AA2951290D9Q42375647-0C3DF6D0-4ECD-4A22-93EB-193AC57858FEQ44129027-04E9FB5E-7AD6-493A-868F-55F53D1692F9Q45069872-3C3F5A72-FB54-458B-AD97-8A5040339906Q46156296-23B4BFB7-0302-43D8-9271-3F3C5C68E563Q46813053-DB611CB8-35B9-4725-936B-59975E0A73D7Q47114292-4EB4B046-9EFB-4A9D-8FD8-A9CBC394FE71Q47201402-B3EDEA06-BBE5-4AC9-8610-C217B72D02D9Q47205297-AD941020-2D24-4CC1-80CB-67ED44E883CEQ47615113-25E8263D-CE3A-4D34-8E3C-F8620A4D07A0Q47787189-3DEED43C-1ED4-4BA8-BB6F-36BD4777547EQ48342063-0D98BBAD-709A-4601-B50C-CBCF6AE0F7D1Q52624982-20B0482F-01CC-4FE3-9FAC-803670E23CA0Q53098304-C163F3BF-2EB7-4954-A311-BF9AF38D37B4Q54390436-59F2DE3D-5317-4C1F-AF19-0D6DBE8A69C3Q55049196-8405BCE3-1CE2-4A16-8E20-C81147D0C58AQ55190939-C9C61498-31F8-4BEC-8E8A-37475EAA2E38Q55324101-E43E06F5-551A-409E-897D-60354C7710E1Q55332862-8414C983-2252-4956-A0F0-65C781075277Q55379081-21EA4C4D-E8FB-4930-B3DA-BCC2AF677DCEQ55394717-EAD88449-AD79-4876-8320-1A7B952B1C01Q57112362-70D395C9-FB7F-49AD-92D9-852322DD3060
P2860
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Development and Validation of ...... Ursodeoxycholic Acid Therapy.
@en
type
label
Development and Validation of ...... Ursodeoxycholic Acid Therapy.
@en
prefLabel
Development and Validation of ...... Ursodeoxycholic Acid Therapy.
@en
P2093
P50
P1433
P1476
Development and Validation of ...... g Ursodeoxycholic Acid Therapy
@en
P2093
Andrew L Mason
Angela Cheung
Annarosa Floreani
Bettina E Hansen
Christophe Corpechot
Cyriel Y Ponsioen
Frederik Nevens
Global PBC Study Group
Harry L A Janssen
Henk R van Buuren
P304
1804-1812.e4
P356
10.1053/J.GASTRO.2015.07.061
P407
P50
P577
2015-08-07T00:00:00Z